



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,481	06/17/2005	Andrew Austen Mortlock	100937-1P US	2446
44992 7590 06/28/2007 ASTRAZENECA R&D BOSTON 35 GATEHOUSE DRIVE WALTHAM, MA 02451-1215			EXAMINER TRUONG, TAMTHOM NGO	
			ART UNIT 1624	PAPER NUMBER
			MAIL DATE 06/28/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/539,481

Applicant(s)

MORTLOCK, ANDREW AUSTEN

Examiner

Tamthom N. Truong

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-10 and 15-24 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-8, 10 and 15-24 is/are rejected.
- 7) ☒ Claim(s) 9 is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 10-4-05.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____.

DETAILED ACTION

Applicant's preliminary amendment of 6-17-05 is acknowledged.

Claims 1-10 and 15-24 are pending.

Claims 11-14 are cancelled.

Claim Rejections - 35 USC § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

1. **Scope of Enablement:** Claims 1-8, 10 and 15-24 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating tumour cell, does not reasonably provide enablement for various cancers and other disorders associated with Aurora kinase. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The following factors have been considered in the determination of an enabling disclosure:

- (1) The breadth of the claims;
- (2) The amount of direction or guidance presented;
- (3) The state of the prior art;

Art Unit: 1624

- (4) The relative skill of those in the art;
- (5) The predictability or unpredictability of the art;
- (6) The quantity of experimentation necessary;

[See *Ex parte Forman*, 230 USPQ 546 (Bd. Pat. App. & Int., 1986); also *In re Wands*, 858 F.2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988)].

The breadth of the claims: Claims 1 and dependent claims thereon recite formula (I) which covers a large Markush group covering many combinations of rings and functional groups.

Claim 15 recites: "A method treating...a disease in which the inhibition of one or more Aurora kinases is beneficial to the treatment..." which includes hyperproliferative diseases such as cancer. The term "hyperproliferative disease" encompasses more than just cancer. It also covers embryogenesis, psoriasis, and many other normal growths. Although the specification names a few cancers, the language is open-ended and includes an indeterminate number of diseases or growth in general. Thus, the scope of said claims is unduly broad.

The amount of direction or guidance presented: The specification only describes a few *in-vitro* assays to show the inhibition on Aurora-A kinase, Aurora-B kinase and cell proliferation as well as cell cycle analysis. However, it is not clear which compounds have been tested, the IC₅₀ ranges from 0.3 nM to 1000 nM (or 10,000 nM) which seems rather general. Furthermore, it appears that only one cell line (SW620) was used for said assays. It is not apparent what type of cell line it is (lung, breast, skin, etc.). Thus, there seems to be no correlation between the tested results and the treatment for various cancers recited in or covered

Art Unit: 1624

by the instant method claims. Therefore, the specification does not provide sufficient enablement to select an effective compound from such a large Markush group for treating various cancers and diseases covered by the above claims.

The state of the prior art: As evident by the teaching of **Bischoff et. al.** (cited in the specification), aurora kinases are implicated in colorectal cancers and solid tumors. Thus, the state of the art does not support the generic scope of treating "hyperproliferative diseases" or various cancers as recited in the instant claims 15 and 16.

The relative skill of those in the art: Even with the advanced training, the skilled clinician would have to carry out extensive research to select an effective compound from the large Markush group of formula I. Not only one has to determine an IC_{50} value, but also *in-vivo* activity to establish an LD_{50} , therapeutic index and pharmacokinetic profile for each compound. Given a large Markush group of the claimed formula I, such a task would require a tremendous amount of effort, time and resource.

The predictability or unpredictability of the art & The quantity of experimentation necessary: The pharmaceutical art has been known for its unpredictability due to various conflicting path ways, or biological factors that are sometimes genetically unique to individuals. In the instant case, the *in-vitro* IC_{50} values provided in the specification does not adequately correlate the *in-vivo* activity of the claimed compounds in treating various cancers covered by the above claims.

There is no reasonable basis for assuming that the myriad of compounds embraced by the broader generic claims will all share the same physiological properties since they are so

structurally dissimilar as to be chemically equivalent and there is no basis in the prior art for assuming the same. Note, **In re Surrey** 151 USPQ 724 regarding sufficiency of disclosure for a Markush group. Also see MPEP 2164.03 for enablement requirements in cases directed to structure-sensitive arts such as the pharmaceutical art. It is well established that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved”, and physiological activity is generally considered to be unpredictable. See **In re Fisher** 166 USPQ 18. Also, See **Hoffman v. Klaus** 9 USPQ 2d 1657, and **Ex parte Powers** 220 USPQ 925 regarding type of testing needed to support *in vivo* uses.

Note, the Federal Circuit has repeatedly held that “the specification must teach those skilled in the art how to make and use the **full scope** of the invention without ‘undue experimentation’”.

Thus, given the unpredictable nature of the art, and the vast number of compounds claimed herein, one skilled in the art will have to carry out undue experimentation to practice the method of treatment recited in the above claims.

Claim Rejections - 35 USC § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1624

2. Claim 15 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 15 recites the mechanism of action of "inhibition of one ore more Aurora kinases", which is indeterminate . Defining a disease(s) by its (their) underlying cause renders the scope of intended uses indeterminate since the claim language may read on diseases not yet known to be caused by or affected by such action or in ways not yet understood. Additionally, determining whether a given disease responds or not to sodium-hydrogen exchange inhibition involves much experimentation since a negative response from one patient does not mean the drug isnt useful as no drug has 100% effectiveness. Thus what "success rate" determines if a particular inhibitor is effective and how many patients (and dosage regimens) need to be tested? The test for determining compliance with 35 USC 112, par.two is whether applicants have clearly defined "their" invention not what may be discovered by future research as this type of claim language clearly requires.

Claim Rejections - 35 USC § 112

3. Claim 9 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Species recited in claim 9 have a phosphate group which is not taught or fairly suggested by the prior art of record.

Art Unit: 1624


References cited on PTO-890

4. References cited on PTO-890 (US 6,919,338) has one common inventor. No issue of Obviousness-type double patenting is noted since the claims in US'338 do not have a phosphate group as a terminal group.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M, T and Th (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Tamthom N. Truong
Examiner
Art Unit 1624

6-23-07


JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1000